Status:
COMPLETED
Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan
Lead Sponsor:
Karaganda Medical University
Collaborating Sponsors:
McMaster University
Conditions:
Covid19
Vaccine Adverse Reaction
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess the safety, reactogenicity, and immunogenicity of Gam-COVID-Vac (Sputnik V) vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2...
Detailed Description
Sputnik V (Gam-COVID-Vac) is an adenoviral vector vaccine developed by The Gamaleya Research Institute of Epidemiology and Microbiology (Moscow, Russia), registered and approved by the Ministry of Hea...
Eligibility Criteria
Inclusion
- Participant must be healthy (in the physician's clinical judgment and as confirmed by medical records, and physical examination at screening).
- Willing to give informed consent, and answer short questionnaires on past exposure to COVID-19 and post-vaccination reactogenicity.
- Willing to comply with the requirements of the protocol.
Exclusion
- Participant shows signs of an acute illness (excluding minor illnesses such as diarrhea or mild upper respiratory tract infection).
- Participant has a positive laboratory-confirmed test result for SARS-CoV-2 infection at screening.
- Deemed by investigators to be unlikely to complete study protocol.
Key Trial Info
Start Date :
April 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2023
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT04871841
Start Date
April 5 2021
End Date
June 20 2023
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karaganda Medical University
Karaganda, Kazakhstan, 100008